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Chapter 1
Introduction

Since 1966, the United States Medicare program has insured seniors over the age of
sixty-five and individuals with certain disabilities. It covers a range of medical services,
including hospital stays, physician visits, preventative benefits, and starting in 2006, prescription
drugs. The Medicare program consists of two major components. The first is Hospital Insurance
(HI), or Medicare Part A, which helps pay for hospital, home health, skilled nursing facility, and
hospice care. The second, called Supplementary Medical Insurance (SMI), consists of Medicare
Part B and Part D. Medicare Part B helps pay for physicians, outpatient hospitals, and home
health care for “senior” or disabled individuals. Part D is the newest addition to Medicare and
provides subsidized access to drug insurance coverage on a voluntary basis (Trustees, Insurance
et al. 2011). The aforementioned programs offer essential medical services to a growing
population of retiring individuals.
In 2010, 47.5 million people were covered by Medicare: 39.6 million aged sixty-five and
older, and 7.9 million disabled (Trustees, Insurance et al. 2011). This number will increase
substantially over the next ten years as the baby boomer generation reach the eligible age for
Medicare and qualify for benefits. Total Medicare expenditures were $523 billion in 2010 and
are projected under current law to increase in future years at a somewhat faster pace than either
workers’ earnings or the economy overall (Trustees, Insurance et al. 2011). The increasing
demands on the Medicare program will force possible additional reform decisions regarding the
benefits offered in the future. This analysis looks into the specific demographics that utilize the
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prescription drug plans (PDP) offered in Part D and those who lack coverage to pay for the
necessary prescriptions and the possible consequences that arise because of that.
The figure below shows a timeline detailing major changes to the Medicare program
since its inception in 1966 to 2020 when the Obama Health Care Plan will complete the
elimination of the coverage gap.

1965

•The Social Security Act of 1965 was signed into law July 30, 1965, by President Lyndon B. Johnson as
amendments to existing Social Security legislation. This legislation included the establishing of the Medicare
program.

2003

• December 8, 2003 The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) was
passed by the House (220-215) and the Senate (54-44) in November and signed into law (Public Law 108-173) by
President Bush on December 8, 2003, providing a new outpatient prescription drug benefit under Medicare
beginning in 2006. In the interim, it created a temporary prescription drug discount card and transitional
assistance program.

2006

•In January 2006, the Medicare Drug Benefit went into effect and Medicare beneficiaries began receiving
subsidized prescription drug coverage through Part D plans. As required by law, the Medicare Trustees
calculated for the first time that general revenues will exceed 45% of total Medicare outlays within a seven-year
period

2008

2010-2011

2012-2020

•The Medicare Trustees issued a "Medicare funding warning" in 2008, as required by law, indicating general
revenues would exceed 45percent of total Medicare spending within a seven-year period.

•The Patient Protection and Affordable Care Act of 2010 included a Coverage Gap Rebate of $250 payment in
2011 & 50% off name brand drugs while in donut hole

•The coverage gap will be phased out through annual increases in discounts until 2020, when the consumer’s
share of the costs will be reduced to 25 percent for both brand-name and generic drugs.

Figure 1: Medicare Part D Timeline
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The Medicare Prescription Drug Improvement and Modernization Act (MMA) of 2003
represented the largest expansion of Medicare benefits since the program’s inception. The MMA
subsidized voluntary enrollment of Medicare eligible individuals in any of several PDPs with
the ultimate goal of optimizing therapeutic outcomes by improving medication use and reducing
adverse events ( e.g. hospitalizations and ambulatory use). In 2007, Medicare Part D covered 24
million beneficiaries and cost the federal government $39 billion, an average of $1,600 per
individual enrolled, not including out-of-pocket costs paid by the enrollee. In 2010, Part D had
$62 billion in total expenditures, and the cost is projected to grow as per capita healthcare costs
continue to outpace gross domestic profit (GDP) growth and as the baby boom generation ages
(Aaron, Jeanne Lambrew et al. 2008; Trustees, Insurance et al. 2011). The Medicare Trustees
Report estimates that 29.2 million individuals will be enrolled in Part D by 2011 with an
intermediate estimate of 45.6 million enrolled by 2020 (Trustees, Insurance et al. 2011). The
figure below shows the historical data and estimates for Medicare Part D enrollment from 200620. The supplementary table lists expenditures for Part D as a percentage of GDP. The projection
period fully allows for the presentation of anticipated future developments, such as the impact of
a large increase in enrollees during 2010-30. The increase in the number of beneficiaries will
occur because the relatively large number of persons born during the period between the end of
World War II and the mid-1960s (known as the baby boom generation) will reach eligibility age
and begin to receive benefits. Moreover, as the average age of Medicare beneficiaries increases,
these individuals will experience greater health care utilization and costs, thereby adding further
to growth in program expenditures (Trustees, Insurance et al. 2011).
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The two figures below show to important historical and estimated numbers associated
with Medicare Part D. The first figure, Figure 2 shows the enrollment in Medicare Part D from
the 2006 implementation to 2020. Figure 3 display’s the expenditures on Medicare Part D as a
portion of Gross Domestic Product.

Figure 2: Enrollment in Medicare Part D Plans: All Beneficiaries
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Figure 3: Part D Expenditures as Part of Gross Domestic Product

A controversial aspect of the Medicare Part D benefit design was the inclusion of a
doughnut hole, or gap in coverage, defined as the difference in the initial coverage limit
and the catastrophic coverage threshold. The gap was included to keep the cost of the
program within the amount specified by the congressional budget resolution. The coverage gap,
defined for the purpose of this paper, is when a beneficiary reached $2,400 in total drug costs and
ended when catastrophic benefits started, i.e. total drug costs reached $5,451 (Florian Heiss
2007; Hoadley, Hargrave et al. 2007; Tseng, Dudley et al. 2009). The figure below references the
5

diagram created for the Hoadley paper, which visually gives a detailed breakdown of the out-ofpocket expenditures and total drug costs that define the coverage gap in Medicare Part D.

Figure 4: Medicare Part D Coverage Levels

Research suggests many Medicare Part D recipients are making suboptimal choices by
either not enrolling in Part D or by choosing a suboptimal plan (Florian Heiss 2007; Lichtenberg
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and Sun 2007; Zhang 2010). By incorrectly selecting a suboptimal plan, the gap can greatly
affect elderly individuals' drug adherence, income, and health when faced with high,
unsubsidized medication costs.
For most beneficiaries enrolled in Medicare Part D, the drug coverage offered by the
PDPs sufficiently covers acute and chronic medication expenses. Several studies of the coverage
gap found that around 40% of beneficiaries enter the gap with 10% reaching the out-of-pocket
level to push them into catastrophic coverage (Hoadley, Hargrave et al. 2007). Further, research
suggests that individuals who are close to reaching the gap, or have reached it, may stop taking
medications, lower their medication adherence, or switch to less effective substitutes. The U.S.
Department of Health and Human Services estimates that more than a quarter of Part D
participants stop following their prescribed drug regimen when they hit the doughnut hole [CMS,
Medicare.gov]. If at-risk beneficiaries can be identified before they enroll in a specific PDP,
these individuals can select optimal plans that minimize their amount of out-of-pocket (OOP)
drug costs while maximizing health outcomes.
For older and senior women, exorbitant OOP expenses can lead to crippling financial
burden, precipitating medical debt and/or the avoidance of necessary medical care (Song, Chang
et al. 2006). Coverage gaps also discourage older and senior women from seeking preventive
health care and other needed services that could go a long way to prevent future illnesses and
healthcare costs. As a result, high OOP costs and benefit gaps have potentially negative financial
and health-related consequences for older and senior women.
Early analyses of the effects of Medicare Part D found an individual’s probability of
reaching the gap depends not only upon income, but also upon socioeconomic status, education,
7

age, ethnicity, and gender (Daniel and Malone 2007; Bayliss, Ellis et al. 2010). In the analysis to
follow, data is used from the Medical Expenditure Panel Survey for the three years after the
plans’ implementation in 2006 to evaluate whether the short-run effects previously observed, e.g.
disproportionate likelihood of entering the gap for women versus men, hold over time. Then,
possible correlation between OOP drug costs and drug non-adherence after an individual enters
the coverage gap are assessed. Demographics and characteristics may be key in identifying atrisk populations before it is too late. The conclusions derived from this research could assist
“seniors'” ability to navigate the sea of choices available with Medicare Part D PDPs and
increase access to necessary medications.
Entry into the coverage gap will be defined by the 2007 listing of coverage entry when
beneficiaries’ total drug costs equal $2,400, and ends when a beneficiary has spent $5,451 in
total drug costs and, therefore, the equivalent of $3,850 in OOP costs (Hoadley, Hargrave et al.
2007; Tseng, Dudley et al. 2009).
The second part of the analysis concentrates on the impact the coverage gap may have on
elderly beneficiaries’ drug adherence. The World Health Organization has researched and defined
adherence to medication as the degree to which the use of medication by the patient corresponds
with the prescribed regimen (Organization 2003; Organization 2003). Five categories have been
identified in previous literature as reasons for medication non-adherence; they are expressed in
the figure below. Examples associated with the five categories of non-adherence are:
1. Health System: Poor quality of provider-patient relationship, poor communication, lack of
access to health care or lack of continuity of care.
2. Condition: Asymptomatic chronic condition disease, meaning there is a lack of physical cues
as in mental health disorders.
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3. Patient: Physical impairments like vision problems or impaired dexterity, cognitive
impairment – be it psychological/behavioral.
4. Therapy: Complexity of regimen or negative side effects.
5. Socioeconomic: Low literacy, high medication costs, or poor social supports.

Figure 5: WHO: Five Reasons for Medication Non-Adherence

All of the factors within the five categories listed above impact the effectiveness of a
patient’s medication regiment and health outcomes (Organization 2003; Ho, Bryson et al.
2009). The second hypothesis of this paper focuses on the socioeconomic reasons for non-
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adherence and the relationship with the lack of prescription drug coverage in Medicare Part
D’s coverage gap.
According to the analyses used throughout this project, women are almost 20-23% more
likely to reach the coverage gap versus their male counterparts. This confirms the previous
literature conclusion that reaching the coverage gap depends on more than income and comorbidities. With 56% of the 2010 Medicare Part D population being women, further research
into why they reach the coverage gap more often than men could make a substantial difference in
future health outcomes (Trustees, Insurance et al. 2011).
Previous literature has concluded that there is a relationship between the coverage gap
and drug adherence (Anonymous 2006; Hsu, Fung et al. 2008; Hsu, Price et al. 2010).While it
was interesting to find there was positive correlation between gap entry and gender. The surprise
was that gender did not pay a significant role on an individual’s drug adherence.

Chapter 2
Literature Review

The Medicare Part D prescription drug benefit has been studied by numerous authors
over the last five years since its implementation. In this section, those findings that are directly
related to this analysis will be reviewed.
The first published articles about Medicare Part D concentrated on comparing the
population of individuals age sixty-five and older before and after Medicare Part D was
implemented (Patel and Davis 2006; Skrepnek, Denarie et al. 2008; Safran, Strollo et al. 2010).
Knowledge regarding the coverage gap didn’t appear until data started to accumulate, and
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researchers discovered a significant amount of beneficiaries fell into the gap each year
(Anonymous 2006; Delate, Raebel et al. 2008; Zhang, Donohue et al. 2009). Once individuals
were identified as reaching the coverage gap further analysis could start on the variables that
could explain why they exceeded the expenditure limit (Daniel and Malone 2007; Said, Li et al.
2009; Bayliss, Ellis et al. 2010; Ettner, Steers et al. 2010). Current published papers address the
problems in identifying those individuals who reach the coverage gap or the affect the gap has on
drug adherence. These analyses build off of both hypotheses, utilizing a comprehensive data set
to make observational statements about the population for possible future research and
interventions.
In 2006, Patel and colleagues commenced research into the newly-developed prescription
drug subsidy program by studying how beneficiaries with higher drug utilization may face higher
OOP costs. With the prescription drug benefit in its first year of implementation, specific data on
Part D beneficiaries was unavailable, so the Medicare Current Beneficiary Survey Cost and Use
data for 1997 through 2001 were used to estimate the impact of the standard Part D benefit upon
drug expenditures. The results indicated that beneficiaries face substantial total and OOP annual
expenditures for medications, causing most to reach the Part D benefit gap. Patel et al. argue that
higher OOP costs may lead to reductions in spending and medication use, thereby causing
treatment gaps, which, in turn, may lead to increased use of medical services (Patel and Davis
2006).
Daniel et al. (2007) discussed the implication of medication therapy management
programs (MTMPs) on beneficiaries with drug expenditures above $4,000, multiple comorbidities, and multiple prescription drugs. MTMPs benefit individuals who use several
medications, those who have several health conditions, those who have questions or problems
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with their medications, those who are taking medications that require close monitoring, those
who have been hospitalized, and those who obtain their medications from more than one
pharmacy. Using Medical Expenditure Panel Survey data from 2002-03, he examined the
expenditures of older adults over the age of sixty-five on the probability of reaching the coverage
gap. His results indicated that characteristics other than drug use, such as having functional
limitations or requiring help with activities of daily living, can be used to identify potential
MTMP candidates (Daniel and Malone 2007). The use of medication therapy programs might be
able to assist individuals from reaching the coverage gap in the future because it can identify and
manage the prescriptions and improve drug adherence.
Lichtenberg et al. (2007) used a difference-in-difference design to estimate the effects of
Medicare Part D on seniors’ prescription drug use and expenditures. His results indicated that
although crowding out occurred due to Medicare Part D, it was not necessarily an inefficient
program. In his analysis, crowding out implied that large increases in public spending are
required to obtain relatively small increases in prescription drug use by the elderly. His results
concluded that Medicare Part D reduced the total amount paid by patients by only a small
percent. It increased the amount paid by third parties by a much larger percent. His conclusion
was that overall Medicare Part D seems to have had a negligible impact on the overall price of
prescription drugs. He conceded that while crowding out occurred with only negligible impacts
on price, previous studies suggested an inverse relationship between copayments and compliance
in all risk groups and indicated that Medicare Part D probably reduced Medicare Part A and Part
B spending (Lichtenberg and Sun 2007).
Hoadley et al. (2007) analyzed nationwide patient-level retail pharmacy claims for Part D
enrollees, and found that a large share of Medicare Part D enrollees who take prescription drugs,
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and do not receive low-income subsidies, have spending in the coverage gap. Of those that fall
into the coverage gap, only a small share will pass though the gap and eventually qualify for
catastrophic coverage. Moreover, they found that some enrollees who reached that gap made
changes to their drug regimen, including stopping their medications altogether (Hoadley,
Hargrave et al. 2007).
Hsu et al. (2007) surveyed community-dwelling Kaiser Permanente-Northern California
Medicare Advantage beneficiaries, age sixty-five or older, to assess beneficiaries’ knowledge of
cost-sharing and awareness of the coverage gap. They found that one third of beneficiaries
reported cost-coping behavior, reduced adherence, or experienced financial burden. In
multivariate analyses, beneficiaries with lower household income more frequently reported these
cost responses. The conclusion was that limited knowledge is associated with fewer reports of
cost responses overall but is associated with more reports of financial burden (Hsu, Fung et al.
2008).
Madden et al. (2008) noticed that the previous literature on Medicare Part D did not
evaluate the impact of Medicare Part D on cost-related medication non-adherence (CRN), which
has been a persistent problem among seniors in the United States. His research objective was to
estimate changes in CRN and forgoing basic needs to pay for drugs following Part D
implementation. He used the Medicare Current Beneficiary Survey and logistic regression
analyses to isolate his results. The unadjusted, weighted prevalence of CRN was 15.2% in 2004,
14.1% in 2005, and 11.5% after Part D implementation in 2006. Madden et al. concluded that
evidence exists for a small but significant overall decrease in CRN and the forgoing of basic
needs following Part D implementation, but there was no net decrease in CRN after Part D for
the sickest beneficiaries (Madden, Graves et al. 2008). His findings suggest that the intensive
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medicine needs and financial barriers to access among the sickest beneficiaries may be related
to other factors.
In 2010, data-rich articles on Medicare Part D began to appear in a variety of medical and
economic journals. The literature consensus in the first five years after Medicare Part D’s
implementation is that characteristics of beneficiaries who reach the coverage gap, and the
unintended consequence of non-adherence due to the coverage gap, were important indicators of
Plan D’s efficacy. Identifying individuals, who will reach the coverage gap, and intervening to
decrease that number through beneficiary coverage education and medication therapy
management, will mitigate the number of women who fall into the coverage gap each year.
Most of the relevant articles cited for this paper use data from the Medicare Current
Beneficiary Survey, National Pharmacy chains, and phone surveys. Only two of them used
MEPS data (Daniel and Malone 2007; Millett, Everett et al. 2010), and these studies were limited
by data availability, focusing on the years before or directly after the implementation of Part D.
The three studies closest to this work are those by Ettner, Roblin, and Daniel, which are
mentioned above. Ettner’s and Roblin’s papers stand out because both came to the conclusion
that females had a greater probability of falling into the coverage gap than males. Ettner used
pharmacy data from 2005-06 with census data and examined the co-morbidities and
demographics associated with drug entry and exit. The results indicated that 15.9% reached the
coverage gap, and women had a 25% higher chance of gap entry than men (Ettner, Steers et al.
2010). Roblin employs a different data set from Kaiser Permanente Georgia to identify Medicare
Advantage Prescription drug plan enrollees who meet or exceeded the Part D coverage gap in
two consecutive years and identify characteristics that put them at risk for repeat entry.
Interestingly, while most studies found an increased likelihood of coverage gap entry with
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increased patient age and co-morbidities, Roblin found a positive association of repeat gap entry
among females (Douglas W. Roblin and Matthew L. Maciejewsji 2011). Methodologically, this
work most closely follows Daniel et al., which also used the MEPS data.

Chapter 3
Methods

Data:
The Medical Expenditure Panel Survey (MEPS) is a nationally representative survey that
provides representative estimates of health care use, expenditures, payments, health insurance
coverage, and demographic information for the U.S. civilian non-institutionalized population.
The sample is drawn from respondents to the National Health Interview Survey conducted by the
U.S. National Center for Health Statistics. The Survey is split into three separate parts: the
Household component (HC), the Medical Provider Component (MPC), and the Insurance
component (IC). The Household component includes five rounds of patient interviews covering
two full calendar years. Using computer assisted personal interviewing (CAPI) technology, the
information about each participating household member is collected and compiled from
interview to interview. One reporting individual, on behalf of his/her family, provides the data
collected for each reported household. The set of households selected for each panel of the
MEPS HC constitute a subsample of households participating in the year survey. This dataset
provides a representative sample of the U.S. civilian non-institutional population, including black
and Hispanics, recognizing an oversampling of minorities.
The Household Component (HC) represents the core survey in which households and
individuals within households are sampled. Detailed, self-reported data are collected on
15

demographic characteristics, health conditions, health status, income, health insurance coverage,
and employment. The HC uses an overlapping panel design in which data are collected over a
series of five rounds (interviews) over a two and a half year period for each panel. The collected
data, however, cover a complete two year period. A new overlapping panel is sampled and
launched each year. Annual data are then generated by combining the last three rounds (3, 4, and
5) of the previous panel and the first three rounds (rounds 1, 2, and 3) of the new panel. Since
MEPS began in 1996 with panel 1, this study will use data from collection rounds in years 2006,
2007, and 2008. Any expenditure data obtained from the MEPS-HC were self-reported data
(Quality 2011).
This data used for our analysis come from the Full Year Health Care Consolidated files
for 2006, 2007, and 2008. Analyses were run separately for each year to identify specific
variables related to the descriptive statistics. Then, the sample size data files were consolidated
and weighted to create a population that is representative of the United States to run the
regression analysis.
The chart below illustrates the timing and relationship between panels, rounds, and
calendar years. For example, looking at the data collection by panel, panel 12 consists of five
rounds of interviews; with rounds 1-3 providing data for 2007 and rounds 3-5 providing data for
2008. Looking at the data collection by year, data for the year 2008 consists of data collected
from rounds 3-5 of panel 12 and rounds 1-3 of panel 13.
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Figure 6: MEPS Panel Design for 2006-2008
Statistical Analysis:
The initial statistical analysis was performed by acquiring the relevant data from the
Medical Expenditure Panel Survey (MEPS). The population of Medicare Part D eligible
individuals was defined as anyone over the age of sixty-five at the start of 2006. The expenditure
criteria for gap entry and exit came previously mentioned articles. Then, important variables
were flagged, as identified by the literature, along with a subset of additional markers to allow us
to control for gender. Once the data were parsed and processed, descriptive statistics for each
17

year (2006 through 2008) were assembled to establish the overall characteristics of the
population.
The data sets were then combined and weighted using STATA 11.0 to give an overall
population estimate for the United States, given the original sample size. Next, a bi-variate two
by two analysis was run on all variables for those that entered the coverage gap to acquire pvalues and identify significance.
Survey-weighted logistic regression identified factors associated with meeting the
expenditure threshold. Unbiased population point estimates were obtained by adjusting for
survey non-response, post stratification, and oversampling of blacks and Hispanics using MEPS
person-level weights. The standard errors were adjusted for non-independence of observations
due to complex multistage sampling by specifying the strata and primary sampling units for each
respondent.
For the multivariate analysis, we used a generalized linear model (GLM). The basic GLM
mathematical model is defined as:

The level of the individual beneficiary reaching the coverage gap was defined as a binary
outcome coded 1 or 0, based on the level of out-of-pocket expenditures. We also coded a
measure for the characteristics of reaching the gap, which can be between 0 and 1. The “variable
gap” is a measure of the total contribution of all the independent variables used in the model.
When this model is run with no covariates, the output will produce a constant which, if
exponentiated, will be the estimate of beta. When covariates are included, the exponential of the
constant term will be a fitted beta, or the reference combination of the covariates. The
exponential of a coefficient for a covariate will be the relative risk for that covariate.
18

Each of the regression coefficients describes the size of the contribution of that risk factor
or characteristic. A positive regression coefficient means that the explanatory variable increases
the probability of the outcome, while a negative regression coefficient means that the variable
decreases the probability of that outcome; a large regression coefficient means that the risk factor
strongly influences the probability of that outcome, while a near-zero regression coefficient
means that that risk factor has little influence on the probability of that outcome.
Logistic regressions were used to estimate the probability of reaching the coverage gap as
a function of age, gender, ethnicity, income, co-morbidity, reported health, education, and drug
expenditures. The basic logit mathematical model is defined as:
P(y=1|x) = P(y=1| x₁, x₂,…,xₐ),
Where x is used to denote the full set of explanatory variables. In this case y is a gap
indicator, and x contains all the various individual characteristics a beneficiary may have that
could affect gap entry. These include age, co-morbidity, gender, income, ect. To specify the logit
model the assumption is that the response probability is linear in a set of parameters. When y is a
binary response variable (i.e. taking on values of 0 or 1) the equation looks like the one below:
P(y=1| x) = G(β₀+ β₁gender+β₂race+β₃income+β₄co-morbidity+β₅income+…βₐxₐ)
The resulting parameter estimates were used to provide models of patients reaching the gap and
standardized to the underlying population characteristics.
Maximum likelihood estimation (MLE) was used instead of ordinary least-squares or
weighted least-squares due to the nonlinear nature of the model. The MLE provides the simplest
way of estimating parameters in an unconditional distribution. The basic MLE model is given in
the equation below:
19

A probit analysis was run in addition to the logistic regression to determine if there was a
significant difference in the results. In a probit model, we assume that the probability density
function (PDF) of the error term is a standard normal distribution. The model is also estimated
by using a maximum likelihood algorithm. The coefficients from the probit model are difficult to
interpret because they measure the change in the unobserved variable and the change in one of
the explanatory variables. In this analysis, another measure called “marginal effects” was used to
compare the two.
The logit model is very similar to the probit model, except it is assumed that the function
has a logistic distribution instead of a standard normal. Probit and logit models are among the
most widely used members of the family of generalized linear models in the case of binary
dependent variables. The conventional wisdom is that, in most cases, the choice of the model is
largely a matter of preference.
The second hypothesis postulates the possible relationship between drug adherence and
the coverage gap. The key assumption for the null hypothesis was that people in the coverage
gap are less adherent to their medications. Poor adherence to drug therapies or managed care
plans for chronic conditions severely comprises the effectiveness of treatment. This is a critical
issue congruent with the Medicare Part D coverage gap from both the perspective of quality of
life and of health economics. The literature suggests there is a link between the coverage gap
threshold and increased costs due to in-patient and emergency department use(Raebel, Delate et
al. 2008). Improving adherence by limiting the amount of the population that falls into the
20

coverage gap each year would provide a significant positive return by prevention of adverse
health outcomes.
The analysis for the hypothesis will extend the eligible population into three discrete gap
groups (i.e. 1 = individuals who did not hit gap, 2 = individuals in gap at end of year, and 3 =
individuals who got through gap). For each drug code, the individual sum of the quantity was
standardized using the annual prescription data. The resulting z-scores represent the individual’s
annual usage of the drugs. For the chronic conditions, the z-scores of treatment drugs were
averaged to produce a z-score for the individual annual use of drugs used for treatment of the
chronic conditions. This adherence proxy allowed for testing a change either positive or negative
into the different mind sets of beneficiaries surrounding the coverage gap.
A proxy variable was used because given the lack of data on the relevant variable for
adherence, which was RX fill dates, a related but not identical variable of z-scores for drugs
prescribed was used in place of the unobserved variables in the analysis. The z-score variable
corresponded to a point in a normal distribution and as such described how much a point deviates
from a mean or specification point.
Variables:
The variables included to start the separate logistic and probit regressions are listed in the
figure below. Additional variables covering specific demographics and co-morbidities are listed
in multiple tables listed among the appendices.
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Variables Necessary for Hypothesis 2: Drug Adherence

Gap Entry

PMDLAY42
PMDLR42
RX Quantity
RX National Drug Code

TC Codes to Create Groups
Hypertension
Diabetes
High Cholesterol
Arthritis
Depression
Asthma

Figure 7: Basic Logit/Probit Regression Model Variables
The MEPS dataset, including the household component, the prescribed medications files,
and the office event files for 2006-08, lacked usable prescription fill dates to include as variables
related to adherence. A proxy variable using the z-score of each subject by chronic condition was
used to measure adherence across all National Drug Codes. Then the drug quantity was summed
by individual and drug code. The mean (mu) and standard deviation (stddev) was calculated for
each code. The standardized z-score for each individual by drug code and chronic condition
group (given by the equation (x - mu)/( stdev )) was estimated. Using the standardized z- score
as a measure of adherence it was applied across all drug codes. The above method allowed all
negative scores to equal non adherence and all positive scores to equal adherence. The variables
for chronic condition by drug code are listed out below:
Hypertension: TC Codes 42,44,47,48,49,55,303,340
Diabetes: TC Codes 99,372,373
Hyperlipidemia (High Cholesterol): TC Codes 19,173,174,241,252,316,317
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Arthritis: TC Codes 192,194, 257,284
Depression: TC Code 249
Asthma/COPD: TC Codes 125,130,131
Each of the six above condition descriptions above were weighted and run individually by gap
group in STATA to get the mean and confidence intervals. Then an analysis of variance
(ANOVA) was completed controlling for all extremely significant demographics that might
explain means falling outside of the determined confidence intervals. An analysis of variance
(ANOVA) involves comparing random samples from several populations. In this case there were
three gap groups along with each condition. The ANOVA technique was used to test the
adherence by testing the equality of the means among the three gap groups.

Chapter 4
Results
Descriptive Analysis
Tables 1-4 show mean values or proportions of the variables included in the analysis for
the sample as a whole and for each of the variables in the study. These variable sets form the
basis of the models in the multivariate analysis.
The results from the weighted files of the population from 2006 through 2008 are
presented in Table 5. The actual number of observations for individuals over the age of sixty-five
was 14,258, which gave an estimated population size of 149,217,142. The average age was
seventy-four years; 58% were women and 70% were white. The average annual income was
$24,366. In the sample reported, 30% of individuals reached the coverage gap within the range
defined at total drug expenditures greater than $2,400, with only 8% exiting the gap to qualify
23

for catastrophic coverage. In terms of health, 23% of patients reported poor or fair physiological
health, while 10% reported poor to fair psychological health. Almost 97% of the individuals had
been married at least once in their life, and 35% had completed twelve years of education.
Surprisingly, when only considering those elderly individuals who had reached the coverage gap,
60% had completed at least twelve years of education or more.
Table 5 shows the spread of respondent characteristics and drug insurance coverage.
Elderly individuals were generally covered by Medicare, with at least 50% carrying private
insurance for at least some part of the year. Only 10% of the population qualified for Medicaid
and only 0.5% were uninsured for the entire year. The most common ailments suffered by the
elderly were high blood pressure, high cholesterol, arthritis, and diabetes. 11% suffered from
myocardial infarctions, 21% suffered from other manifestations of heart disease, and 11%
suffered from stroke.
Overall, after running statistical analyses to find the p-values for all variables, we
observed that the characteristics of being Hispanic, living in urban areas, having tricare
insurance, other public A insurance, and other public B insurance did not correlate significantly
to patients entering the coverage gap. The variables other option A and other option B assisted in
further editing sources of insurance. Specifically if the respondent reported some type of
managed care and paid something for the coverage, Other Public A Insurance (OPAJA08 –
OPADE08); and if the respondent did not report any managed care, Other Public B Insurance
(OPBJA08 – OPBDE08) (Quality 2011).
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Results for P values were defined as being "very significant" or "extremely significant"
depending on the size of the P value. Results with a P value less than or equal to 0.05, were said
to be significant while a P value less than 0.001 was considered extremely significant.
The P value was defined as a probability, with a value ranging from zero to one. It is the
answer to the question: If the populations really have the same mean overall, what is the
probability that random sampling would lead to a difference between sample means as large (or
larger) than was observed. Reporting results using P values means that random sampling from
identical populations would lead to a difference smaller than you observed in the P value percent
minus one hundred of experiments and larger than you observed in P value percent of
experiments.
Regression Analysis:
Many coefficients were dropped out of the regression analysis due to statistical issues. All
other races, besides black and white, were not included because they only accounted for a total of
10% of the estimated population. The second variable used for education, based on highest
degree earned, was not included because of the high percent of people who reported “other
degree.” There was no way to isolate what degrees fell into the specific category or if the same
person reported a degree twice. Number of years of education was used in the regression analysis
instead. Living in an urban area and if the respondent was comfortable speaking English were
both dropped due to less significant p-values. The region variable was merged into two
categories because the Northeast, Midwest and South had a population size of 31% while the
West was significantly different. Income was grouped into three categories where the reference
group was $20,000-$35,000 per annum compared to the high and low income groups.
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Significant predictors of gap group membership were evaluated using logistic regressions
and are shown in Table 6. Risk factors significantly associated with reaching expenditure
threshold included, age, physiological and psychological reported health, gender, and race, and
whether the individual has issues related to stroke, angina, smoking, income, and body mass
index. Females were 24% more likely than males to encounter the coverage gap (odds ratio =
1.238), while the elderly having a BMI (body mass index) greater than 30% were 54% more
likely than normally weighted individuals (odds ratio = 1.535). Elderly who reported fair to poor
physiological health were 59% more likely to encounter the gap compared to those reporting
average health (odds ratio= 1.586). Individuals who reported fair to poor mental health were only
20% more likely to reach the gap (odds ratio =1.203). Income was not as strong a predictor as
had been originally assumed, with only 2% of the lowest income (less than $20,000 per annum)
group reaching the gap (odds ratio=1.018), while those making between 20,000-$40,000 per
annum increased their chances by 17% compared to the wealthiest group (odds ratio = 1.166).
Marginal effects estimation and probit regressions were run in addition to the logistic
regressions to compare any significant differences. Tables 7-9 provide the details for the
marginal effects and probit regression. Table 10 concludes the differences and identifies which
variables were significant for both types of regression and marginal effects.
Adherence Analysis
The second phase of the analysis modeled a proxy variable for adherence to test the
hypothesis that medication adherence was correlated with the coverage gap. Table 10 starts with
the distribution of individuals who reached each gap group by gender. 66.1% of women did not
reach the gap, 24.7% fell into the gap, and 9.2% went though the coverage gap. Males were
lower with 70.6% not reaching the gap, 20.9% falling into the gap, and 8.5% reaching
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catastrophic coverage. The data was summed by the national drug code through the designated
chronic condition groups. Then using the standardized z-score the means and confidence
intervals were collected to compare conditions by gap groups. Tables 11-13 provide the details
for each model and analysis but there are several significant differences in the usage levels
between groups. The p- values and 95% confidence intervals were used to see which coefficients
had the smallest significance level First, the group that did not reach the gap all had significantly
lower than average usage meaning the p values <.05. The condition means were analyzed by
looking to see if the coefficient was negative or positive and if the confidence intervals were
overlapping between the difference groups. Hypertension had a mean of (-.072), diabetes (-.075),
high cholesterol (-.104), arthritis (-.094), depression (-.144), and asthma (-.077).All were
negative along with negative non-overlapping confidence intervals signifying that they were less
adherent than the average. Group three which passed though the gap only had two conditions
that were significantly higher than the average. Hypertension with a positive lower confidence
interval of (.016) and asthma (.019).
The ANOVA or analysis of variance alaysis, based on the conditions and gap,
distinguished which variables used in the gender regression analysis impacted dug
adherence.The impacted was based on if there was a significant p-valuse associated with the
coefficients. The ANOVA analyzed the overlap in confidence intervals in each condition group
controlling for demographics. The model relating to the hypertension gap had a p-value of
(<.001) signifying very significant, income was significant with (.028), and BMI (.037) had
significant p values. Diabetes had significant p values associated with education (<.001) and
income (.035). Income (.003) and BMI (.001) were also extremely significant variables for high
cholesterol. Body Mass index was the only significant variables associated with depression with
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a p-value at (.036). Age with a p-value of (.019) and region with (.023) were the only significant
variables to asthma. The only condition that did not have an extremely significant p value for the
initial model was arthritis with the gap value of (.071). While, BMI was significant (.032).Tables
14-19 show the results and number of observations for each weighted group. The graph below
summarizes the change in usage of drugs for chronic conditions for those that did not reach the
gap (1), those that reached the gap (2), and those that went though the gap and qualified for
catastrophic coverage (3).
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Figure 8: Mean Z Scores for Hypertension, Diabetes, and High Cholesterol by Gap Groups
(*The bars above represent the 95% confidence intervals)
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Figure 9: Mean z scores for Arthritis, Depression, and Asthma by Gap Group

(*The bars above represent the 95% confidence intervals)
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Chapter 5: Discussion
Limitations:
First, due to the significant results associated with the female gender, one should worry
about any omitted variable bias. It is possible that there may be a variable associated with the
female gender not included in the regression that is biasing the results. Each regression was ran
starting with only relevant variables to the model and then all additional variables were added
that were thought to have a possible effect on the outcome. The likelihood associated with
gender only changed by a percent or two (which is not significant enough to warrant bias).
Second, external validity asks whether the results concluded from this analysis are
generalizable and if so, by whom. MEPS is a large, stratified, random sample survey and should
be an accurate representation of the U.S. demographic.
Third, this study relies on self-reported data, which has the potential for errors in
collection, reporting, and imputation. Respondents may not accurately report their income,
education, or understand how to answer a particular question. MEPS tries to limit reporting error
by significant editing, coding , and accuracy checks before releasing the data causing a three year
lapse between collection and availability.
Finally, while the proxy measurement used in this analysis provides insight into
availability of medication, it does not provide information on the timeliness or consistency of
drug refilling. The adherence variable is normalized and due to the lack of prescription fill dates
in the data can not differentiate if one person was more consistent or timelier with their refill
behavior over another.
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Discussion:
Individuals over the age of sixty five are heavy users of medical services because of a
disproportionally high prevalence of chronic and acute health conditions. Health coverage is
especially critical because health care and prescription drugs are expensive and costs are rising
fast. In fact, health costs continue to climb at a pace that exceeds the growth of income and social
security benefits. Action is necessary to address both the exhaustion of the HI trust fund and the
anticipated excess growth in all Medicare fund expenditures (Trustees, Insurance et al. 2011).
Key points to take away from these analyses are that gender and race are both significant
criteria in identifying individuals who will reach the coverage gap. This hypothesis is significant
because it shows a persistence of gender and race differences in prescription drug utilization
among Medicare beneficiaries. Women in this analysis are more likely to reach the coverage gap
than males and face significant decline in their health due to income constraints once inside the
gap. This can increase the levels of non-adherence to prescription drug regiments, causing
higher rates of hospitalizations and greater cost passed along to tax financed government
programs.
The large number of women who reach the gap, versus other groups, present health
equity issues, especially when developing a functional and equitable healthcare policy in the
United States. Rising drug costs during the coverage gap will mean that an increasing number of
women may be faced with hard choices about their health care and other supportive services they
need to maintain their well-being. The aforementioned analyses point out that equity among the
Medicare Part D beneficiaries is not occurring in our current system.
Further, research into women’s health care and prescription drug usage needs to happen
to ascertain why they are not reaching an optimal amount of drug coverage. It is possible that
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with additional outreach another variable related to gender, that is not gathered in current
questionnaires or literature, could account for the discrepancy in gap entry.
The results from the second hypothesis demonstrate that there may be a difference
among the groups of individuals who reach the gap. Those associated with gap group one whom
did not actually enter the gap showed to be the least adherent to their medication. The rationale
could be that they are less adherent because they are trying to avoid the gap. The second gap
group, who did reach the gap, was more adherent to their medications which could have caused
them to fall into the gap but was still not as adherent as the final group. The final gap group
which passed though the gap to reach catastrophic coverage was the most adherent. This could
be because they knew they would have enough medication costs to send them though the gap.
Meaning, that by filling their prescriptions as prescribed would push them though the gap and
back to coverage as quickly as possible. This finding is significant because breaking the gap into
three groups separates out possible trends in adherence that each group might face, which has not
been done in the previous literature.
Another interesting aspect of the adherence hypothesis was that the significant p values
for each condition in the ANOVA analysis related to why individuals might have that condition.
For example, individuals who purchased medication for diabetes had an extremely significant p
values associated with education level, BMI, and income. An individual suffering from diabetes
may not have the education or the money to understand the relationship between healthy meals,
high weight, and their condition. It is possible that interventions based on the variables with
significant p values for each condition could help lower the amount of individuals who reach the
gap. Further research with data including prescription fill dates could address some of the
limitations associated with the limited adherence proxy in this analysis.
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Conclusions:
There are many barriers seniors encounter as they strive to maintain optimal health as
they grow older, especially in a population faced with chronic conditions and managed care
therapies. This paper attempts to add to the review of what is known about the coverage gap and
what seniors do to avoid entry. The idea of drug adherence is closely tied with blame, be it the
patients, doctors, or insurance companies that pay the bills. By 2020, Medicare Part D should
eliminate the coverage gap and possibly all the adherence problems addressed in this paper.
Realistically, what is required instead is a multidisciplinary approach that develops means of
accurately assessing not only adherence, but those factors, like the coverage gap, that influence
it. Early introduction of reform changes increase the time available for affected individuals and
organizations, including health care providers, beneficiaries, and taxpayers to adjust their
expectations. With prompt action the necessary research and reform possibilities can be
developed in time to address these challenges.
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Appendix for Tables:

Table 1:
For Age 65 and older for years 2006
Master Table of Variables 2006 (n=3,883)
Characteristics

Variable Name and Percent
breakdown of Population

Weighted pop size per year
Age
65-69 (reference group)
70-74
75-79
80-84
85+
Gender
Male
Female
Race/ethnicity
White
Black
Amer Indian/Alaska Native
Asian
Native Hawaiian/Pacific Islander
Multiple races reported
Hispanic
Yes
Education
>12
12
<12
Degrees attained
No Degree
GED
High School Diploma
Bachelor’s Degree
Master’s Degree
Doctorate Degree
Other Degree
Living in Urban Area
Yes

age
1,162 (29.9%)
899 (23.2%)
792 (20.4%)
570 (14.7%)
460 (11.8%)
sex
1,624 (41.8%)
2,259 (58.2%)
racex
3,067 (79.0%)
603 (15.5%)
26 (0.7%%)
144 (3.7%)
8 (0.2%)
35 (0.9%)
hispanx
513 (13.2%)
educyr
1,234 (35.0%)
1,218 (32.7%)
1,273 (34.2%)
hideg
1,289 (33.7%)
149 (39%)
1,559 (40.7%)
376 (9.8%)
197 (5.1%)
75 (2.0%)
185 (4.8%)
msa
3,044 (78.4%)
35

langhm42
3,370 (87.4%)
359 (9.3%%)
128 (3.3%)
enghme42
3,396 (87.5%)
189 (4.9%)
region_42
638 (16.4%)
813 (20.9%)
1,545 (39.8%)
887 (22.8%)
marry_x
1,984 (51.2%)
1,253 (32.2%)
435 (11.2%)
56 (1.4%)
150 (3.9%)
rtlp06
povcat
664 (17.1%)
349 (9.0%)
700 (18.0%)
1,039 (26.8%)
1,131 (29.1%)
rthlth31
558 (14.6%)
980 (25.6%)
1,179 (30.8%)
790 (20.6%)
327 (8.5%)
mnhlth31
1,024 (26.7%)
1,114 (29.1%)
1,238 (32.3%)
362 (9.4%)
95 (2.5%)
bmindex53
1,332 (35.7%)
1,432 (38.4%)
969 (26.0%)
inscov
1,911 (49.2%)
1,924 (49.6%)
48 (1.2%)

Language Spoken at Home
English
Spanish
Other language
Comfortable speaking English
Inapplicable
Yes
Region
Northeast
Midwest
South
West
Married
Married
Widowed
Single
Divorced
Separated
Income
Family income % of poverty line
Less than 1.00 times poverty line
1.01 to 1.24 times poverty line
1.25 to 1.99 times poverty line
2.0 to 3.99 times poverty line
4.00 or more times poverty line
Overall Health (Self Reported)
Excellent
Very Good
Good
Fair
Poor
Mental Health
Excellent
Very Good
Good
Fair
Poor
Mean BMI
Underweight/normal <25%
Overweight 25-29%
Obese >30
Coverage
Any private
Public only
Uninsured
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prve
1,772 (45.6%)
Triev
233 (6.0%)
mcrev
3,802 (97.9%)
mcdev
693 (17.8%)
oparv
34 (0.9%)
opbev
64 (1.6%)
unins
48 (1.2%)

Private Ins
Covered for at least 1 day
Tricare
Covered for at least 1 day
Medicare
Covered for at least 1 day
Medicaid
Covered for at least 1 day
Other Public A
Covered for at least 1 day
Other Public B
Covered for at least 1 day
Uninsured all of 06
Covered for at least 1 day
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Table 2:
For Age 65 and older for years 2007
Master Table of Variables 2007 (n=6,991)
Characteristics

Variable Name and Percent
breakdown of Population

Weighted pop size per year
Age
65-69 (reference group)
70-74
75-79
80-84
85+
Gender
Male
Female
Race/ethnicity
White
Black
Amer Indian/Alaska Native
Asian
Native Hawaiian/Pacific Islander
Multiple races reported
Hispanic
Yes
Education
>12
12
<12
Degrees attained
No Degree
GED
High School Diploma
Bachelor’s Degree
Master’s Degree
Doctorate Degree
Other Degree
Living in Urban Area
Yes
Language Spoken at Home
English
Spanish
Other language

age
2,116 (30.3%)
1,612 (23.1%)
1,393 (19.9)
1,005 (14.4%)
865 (12.4%)
sex
3,030 (43.3%)
3,961 (56.7%)
racex
5,893 (84.3%)
1,082 (15.5%)
16 (.2%)
0
0
0
Hispanx
867 (12.4%)
Educyr
2,361 (35
2,252 (33.4%)
2,127 (31.6%)
Hideg
2,177 (31.5%)
245 (3.5%)
2,928 (42.3%)
747 (10.8%)
350 (5.1%)
140 (2.0%)
329 (4.8%)
msa
5,513 (78.9%)
langhm42
6,082 (87%)
621 (8.9%)
275 (3.9%)
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enghme42
6,0959 (87.2%)
307 (4.4%)
region_42
1,194 (17.1%)
1,512 (21.7%)
2,698 (38.7%)
1,574 (22.6%)
marry_x
3,739 (53.3%)
2,111 (30.2%)
779 (11.1%)
88 (1.3%)
273 (3.9%)
rtlp06
26,483 Mean
Povcat
1,022 (14.6%)
583 (8.3%)
1,248 (17.8%)
1,996 (28.6%)
2,142 (30.6%)
Rthlth42
907 (13%)
1,872 (26.9%)
2,324 (33.4%)
1,420 (20.4%)
443 (6.4%)
mnhlth31
1,733 (24.9%)
2,008 (28.8%)
2,311 (33.2%)
723 (10.4%)
191 (2.7%)
bmindex53
2,465 (36.6%)
2,518 (37.4%)
1,744 (25.9%)
Inscov
3,297 (47.2%)
3,613 (51.7%)
81 (1.2%)
Prve
3,097 (44.3%)
Triev

Comfortable speaking English
Inapplicable
Yes
Region
Northeast
Midwest
South
West
Married
Married
Widowed
Single
Divorced
Separated
Income
Family income % of poverty line
Less than 1.00 times poverty line
1.01 to 1.24 times poverty line
1.25 to 1.99 times poverty line
2.0 to 3.99 times poverty line
4.00 or more times poverty line
Overall Health (Self Reported)
Excellent
Very Good
Good
Fair
Poor
Mental Health
Excellent
Very Good
Good
Fair
Poor
Mean BMI
Underweight/normal <25%
Overweight 25-29%
Obese >30
Coverage
Any private
Public only
Uninsured
Private Ins
Covered for at least 1 day
Tricare
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368 (5.3%)
Mcrev
6,850 (98%)
Mcdev
1,127 (16.1%)
Oparv
40 (.6%)
Opbev
154 (2.2%)
Unins
81 (1.2%)

Covered for at least 1 day
Medicare
Covered for at least 1 day
Medicaid
Covered for at least 1 day
Other Public A
Covered for at least 1 day
Other Public B
Covered for at least 1 day
Uninsured all of 06
Covered for at least 1 day
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Table 3:
For Age 65 and older for years 2008
Master Table of Variables 2008 (n=3,384)
Characteristics

Variable Name and Percent
breakdown of Population

Weighted pop size per year
Age
65-69 (reference group)
70-74
75-79
80-84
85+
Gender
Male
Female
Race/ethnicity
White
Black
Amer Indian/Alaska Native
Asian
Native Hawaiian/Pacific Islander
Multiple races reported
Hispanic
Yes
Education
>12
12
<12
Degrees attained
No Degree
GED
High School Diploma
Bachelor’s Degree
Master’s Degree
Doctorate Degree
Other Degree
Living in Urban Area
Yes
Language Spoken at Home
English
Spanish
Other language

age
1,041 (30.8%)
826 (24.4%)
651 (19.2%)
475 (14%)
391 (11.6%)
Sex
1,448 (42.8%)
1.936 (57.2%)
Racex
2,771 (81.9%)
600 (17.7%)
13 (.4%)
0
0
0
Hispanx
425 (12.6%)
Educyr
1,185 (36.2%)
1,099 (33.5%)
993 (30.3%)
Hideg
1,017 (30.4%)
97 (2.9%)
1,452 (43.5%)
371 (11.1%)
179 (5.4%)
60 (1.8%)
164 (4.9%)
Msa
2,719 (80.4%)
langhm42
2,915 (8601%)
278 (8.1%)
162 (4.5%)
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enghme42

Comfortable speaking English
Inapplicable
Yes
Region
Northeast
Midwest
South
West
Married
Married
Widowed
Single
Divorced
Separated
Income

3,064 (91.6%)
region_42
549 (16.3%)
713 (21.2%)
1,305 (38.8%)
792 (23.6%)
marry_x
1,797 (53.2%)
1,008 (29.8%)
372 (11%)
57 (1.7%)
146 (4.3%)
rtlp06
25,742 Mean
Povcat
526 (15.5%)
280 (8.3%)
618 (18.3%)
987 (29.2%)
973 (28.8%0
Rthlth42
481 (14.4%)
889 (26.6%)
1,123 (33.6%)
608 (18.2%)
241 (7.2)
Mnhlth42
860 (25.7%)
954 (28.6%)
1,129 (33.8%)
321 (9.6%)
78 (2.3%)
bmindex53
1,129 (34.8%)
1,276 (39.3)
842 (25.9%)
Inscov
1,550 (45.8%)
1,806 (53.4%)
28 (.8%)
Prve
1,459 (43.1%)
Triev

Family income % of poverty line
Less than 1.00 times poverty line
1.01 to 1.24 times poverty line
1.25 to 1.99 times poverty line
2.0 to 3.99 times poverty line
4.00 or more times poverty line
Overall Health (Self Reported)
Excellent
Very Good
Good
Fair
Poor
Mental Health
Excellent
Very Good
Good
Fair
Poor
Mean BMI
Underweight/normal <25%
Overweight 25-29%
Obese >30
Coverage
Any private
Public only
Uninsured
Private Ins
Covered for at least 1 day
Tricare
42

165 (4.9%)
Mcrev
3,324 (98.2%)
Mcdev
500 (14.8%)
Oparv
15 (.4%)
Opbev
87 (2.6%)
Unins
28 (.8%)

Covered for at least 1 day
Medicare
Covered for at least 1 day
Medicaid
Covered for at least 1 day
Other Public A
Covered for at least 1 day
Other Public B
Covered for at least 1 day
Uninsured all of 06
Covered for at least 1 day
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Table: 4
Demographics or Characteristics by Health Issues for each year 2006-2008

Demographics or Characteristics
Health Issues

Variable
Name

Percent of
Population
2006

Percent of Percent of
Population Population
2007
2008

Deaf, Yes, no
Blind, Yes, no
Diabetes, Yes, no

Deaf42
Blind42
Diabdx

39, (4.7%)
31, (6.5%)
862, (21.7)

Asthma, yes, no

Asthdx

High Blood Pressure, Yes,
no
High Cholesterol, Yes, no

Hibpdx

Coronary Heart Disease,
Yes, no
Angina Diagnosis, Yes, no

Chddx

404,
(10.6%)
2,525
(66.6%)
1,988
(52.9%)
461
(12.2%)
263
(7.0%)
400
(10.6%)
571
(15.1%)
384
(10.1%)
1,939
(51.4%)
385
(11.1%)

62, (4.3%)
54, (6.1%)
1,600
(23.2%)
665,
(9.5%)
4,688
(68.0)
3,901
(56.8%)
1,096
(15.9%)
558
(8.1%)
746
(10.8%)
1,325
(19.3%)
791
(11.5%)
3,802
(55.3%)
628
(10.0%)

Choldx

Andidx

Heart Attack, Yes, no

Midx

Other Heart Disease Diagnosis, Yes, no
Stroke, Yes, no

ohrtdx

Arthritis, Yes, no

Arthdx

Currently Smoke, Yes, no

strkdx

Adsmok42
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23, (8.4%)
24, (7.0%)
841,
(25%)
291,
(8.6%)
2,336
(69.3%)
2,042
(60.6%)
725
(21.5%)
338
(10.0%)
430
(12.8%)
883
(26.2%)
460
(13.6%)
1,974
(58.6%)
307
(10.0%)

Total Percent for
entire
population

20.4%
9.2%
65.2%
57.1%
16.6%
8.5%
11.3%
21.0%
11.1%
54.7%
9.0%

Table: 5
Demographics or Characteristics of weighted Population on Individuals Who Reached the
Coverage Gap
Demographics or Characteristics

N

Year
2006
2007
2008

149,217,142

Gender
Female
Male

149,217,142

Age
65-69
70-79
80-85+

149,217,142

Race
White
Black
Amer Indian/Alaska Native
Asian
Native Hawaiian/Pacific Islander
Multiple races reported

149,217,142

Hispanic
Hispanic
Not Hispanic

149,217,142

Education
>12
12
<12

146,122,598

Highest Degree
No Degree
GED
High School Diploma
Bachelor’s Degree
Master’s Degree
Doctorate Degree

148,175,826

Estimated %
of population

P-Values
.113

27.9%
29.4%
30.5%
<0.001
31.5%
26.5%
<0.001
26.2%
29.5%
32.5%
.010
29.8%
26.8%
26.2%
24.1%
17.0%
27.3%
.039
26.4%
29.5%
.012
28.5%
28.8%
31.7%
.003
32.2
28.6
29.0
26.8
26.7
25.6
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Other Degree
Diabetes
Yes
No

32.1
147,953,192

<0.001
53.1%
23.2%

Asthma
Yes
No

174,937,536

High Blood Pressure
Yes
No

174,783,061

Cholesterol
Yes
No

174,184,213

Coronary Heart Disease
Yes
No

147,362,032

Angina Diagnosis
Yes
No

147,327,681

Heart Attack
Yes
No

147,677,771

Other Heart Disease Diagnosis
Yes
No

147,441,636

Stroke
Yes
No

147,779,309

Arthritis
Yes
No

147,263,520

Currently Smoke
Yes
No

137,451,298

<0.001
47.4%
27.4%
<0.001
36.0%
16.6%
<0.001
36.7%
19.3%
<0.001
49.2%
25.3%
<0.001
51.5%
27.2%
<0.001
49.6
26.7
<0.001
42.2%
25.9%
<0.001
45.6%
27.3%
<0.001
35.3%
22.0%
<0.001
24.6%
30.1%
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BMI
Underweight/normal <25%
Overweight 25-29%
Obese >30

144,604,461

Insurance Coverage
Any private
Public only
Uninsured

149,217,142

Private Insurance
Covered for at least 1 day
Not covered

149,217,142

Tricare/champva Insurance
Covered for at least 1 day
Not covered

149,217,142

Medicare
Covered for at least 1 day
Not covered

149,217,142

Medicaid/Schip
Covered for at least 1 day
Not covered

149,217,142

Other Public A Insurance
Covered for at least 1 day
Not covered

149,217,142

Other Public B Insurance
Covered for at least 1 day
Not covered

149,217,142

Uninsured entire year
Yes
No
Living in Urban Area
No
Yes

149,217,142

Comfortable Speaking English
Inapplicable
Yes
No

<0.001
24.5%
27.1%
39.5%
<0.001
30.7%
28.0%
2.4%
.0003
30.9%
27.7%
.823
29.7%
29.3%
<0.001
29.6%
10.7%
<0.001
40.7%
28.0%
.459
33.6%
29.3%
.458
31.6%
29.3%
<0.001
2.4%
29.5

149,217,142

.807
29.5%
29.3%

46,347,599

<0.001
29.8%
26.0%
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Region
Northeast (1)
Midwest (2)
South (3)
West (4)

149,217,142

Marital Status
Married
Widowed
Single
Divorced
Separated

149,217,142

Family income % of poverty line
Less than 1.00 times poverty line
1.01 to 1.24 times poverty line
1.25 to 1.99 times poverty line
2.0 to 3.99 times poverty line
4.00 or more times poverty line

149,217,142

Income
0-20,000
20,000-35,000
35,000-300,000

149,074,064

Overall Health (Self Reported)
Excellent
Very Good
Good
Fair
Poor

149,084,581

<0.001
19.9%
21.7%
37.4%
20.8%
<0.001
27.8%
32.5%
28.0%
25.3%
30.5%
<0.001
34.7%
34.6%
30.8%
29.3%
26.0%
<0.001
32.9%
28.6%
24.9%
<0.001
13.1%
21.9%
31.5%
44.6%
53.0%

149,123,508
Mental Health
<0.001
21.9%
Excellent
26.2%
Very Good
34.7%
Good
40.4%
Fair
Poor
43.5%
For Table 5: During 2006-2008 N=14,258, the estimated population size is 149217142, where
29.4% entered the gap and 70.6% didn’t enter the gap. The percentages are of those that entered
the gap.
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Table 6:
Logit Regression Analysis Table
(Adjusted Odds Ratio for likelihood of reaching the coverage gap)
Characteristic
Sex
Race
Diabetes
Asthma
High Blood Pressure
High Cholesterol
Coronary Heart Disease
Angina
Heart Attack
Other Heart Disease
Stroke
Arthritis
Currently Smoke
Private Insurance
Medicare
Medicaid
Uninsured
Age (2)
Age (3)
Repd Mental Health(1)
Repd Mental Health (2)
Repd Health (1)
Repd Health (2)
Income Group (1)
Income Group (2)
Insurance Cov (2)
BMI (2)
BMI (3)

Odds Ratio
1.24
1.25
.455
.633
.745
.897
.924
1.04
.757
.989
1.07
.996
1.03
.701
.400
.657
3.77
1.20
1.36
.924
1.07
.612
1.59
1.02
1.17
.866
1.13
1.54

95% CI
1.12-1.37
1.16-1.34
.374-.554
.493-.814
.640-.868
.834-.964
.849-1.00
.962-1.13
.670-.856
.910-1.07
.948-1.21
.927-1.07
1.00-1.06
.528-.932
.176-.909
.566-.762
1.04-13.67
1.06-1.36
1.18-1.56
.820-1.04
.904-1.27
.537-.698
1.39-1.81
.876-1.18
1.01-1.34
.648-1.16
1.00-1.28
1.33-1.77
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P Value
<.001
<.001
<.001
<.001
<.001
0.003
0.066
0.300
<.001
0.795
0.262
0.912
0.045
0.015
0.029
<.001
0.043
0.002
<.001
0.195
0.462
<.001
0.000
0.808
0.030
0.329
0.044
<.001

Table 7:
Marginal Effects of Logit Regression
Characteristic
Sex
Race
Diabetes
Asthma
High Blood Pressure
High Cholesterol
Coronary Heart Disease
Angina
Heart Attack
Other Heart Disease
Stroke
Arthritis
Currently Smoke
Private Insurance
Medicare
Medicaid
Uninsured
Age (2)
Age (3)
Repd Mental Health(1)
Repd Mental Health (2)
Repd Health (1)
Repd Health (2)
Income Group (1)
Income Group (2)
Insc
BMI (2)
BMI (3)

Dy/Dx
.042
.044
-.156
-.090
-.058
-.022
-.016
.009
-.055
-.002
.014
-.001
.005
-.070
-.182
-.083
.263
.037
.061
-.016
.014
-.097
.091
.003
.030
-.028
.024
.085

95% CI
.022-.062
.030-.058
(-.195)-(-.117)
(-.140)-(-.040)
(-.089)-(-.028)
(-.036)-(-.007)
-.034-.002
-.008-.025
-.07-(-.030)
-.019-.014
-.011-.039
-.015-.013
.001-.011
-.127-(-.014)
-.344-(-.019)
-.112-(-.054)
.008-.518
.013-.060
.034-.088
-.039-.008
-.019-.046
-.123-(-.071)
.065-.118
-.026-.033
.002-.058
-.085-.028
.000-.048
.057-.113
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P value
<.001
<.001
<.001
<.001
<.001
0.003
0.067
0.300
0.000
0.795
0.262
0.912
0.045
0.015
0.028
<.001
0.043
0.002
<.001
0.195
0.426
<.001
<.001
0.808
0.030
0.327
0.044
<.001

Table 8:
Probit Regression Analysis Table
Characteristic
Sex
Race
Diabetes
Asthma
High Blood Pressure
High Cholesterol
Coronary Heart Disease
Angina
Heart Attack
Other Heart Disease
Stroke
Arthritis
Currently Smoke
Private Insurance
Medicare
Medicaid
Uninsured
Age (2)
Age (3)
Repd Mental Health(1)
Repd Mental Health (2)
Repd Health (1)
Repd Health (2)
Income Group (1)
Income Group (2)
Insc
BMI (2)
BMI (3)
cons

Coef
.133
.132
-.299
-.061
-.134
-.050
-.038
.023
-.132
-.001
.079
.016
.017
-.200
-.685
-.266
.500
.110
.186
-.042
.044
-.308
.325
.020
.099
-.088
.103
.324
.137

95% CI
.073-.192
.090-.175
-.393-(-.206)
-.165-.042
-.197-(-.070)
-.089-(-.012)
-.087-.010
-.027-.073
-.195-(-.068)
-.050-.046
.009-.150
-.025-.056
.000-.033
-.364-(-.036)
-1.19-(-.179)
-.353-(-.178)
-.199-1.19
.040-.179
.106-.265
-.113-.029
-.057-.144
-.384-(-.232)
.244-.405
-.066-.107
.017-.181
-.255-.080
.034-.172
.244-.404
-1.76-2.03
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P Value
<.001
<.001
<.001
0.246
<.001
0.010
0.117
0.361
<.001
0.940
0.027
0.448
0.048
0.017
0.008
<.001
0.161
0.002
<.001
0.249
0.396
<.001
<.001
0.649
0.018
0.305
0.003
<.001
0.887

Table 9:
Marginal Effects for Probit Regression
Characteristic
Sex
Race
Diabetes
Asthma
High Blood Pressure
High Cholesterol
Coronary Heart Disease
Angina
Heart Attack
Other Heart Disease
Stroke
Arthritis
Currently Smoke
Private Insurance
Medicare
Medicaid
Uninsured
Age (2)
Age (3)
Repd Mental Health(1)
Repd Mental Health (2)
Repd Health (1)
Repd Health (2)
Income Group (1)
Income Group (2)
Insc
BMI (2)
BMI (3)

Dy/Dx
.044
.044
-.099
-.020
-.045
-.016
-.013
.007
-.044
-.001
.027
.005
.006
-.067
-.228
-.088
.167
.037
.062
-.013
.015
-.102
.108
.007
.033
-.029
.034
.108

95% CI
.025-.064
.030-.058
-.131-(-.069)
-.055-.014
-.066-(-.024)
-.029-(-.003)
-.289-.003
-.010-.024
-.065-(-.023)
-.017-.015
.003-.050
-.008-.019
.000-.011
-.122(-.012)
-.397-(-.059)
-.118-(-.059)
-.066-.399
.014-.060
.035-.089
-.038-.010
-.019-.048
-.128-(-.077)
.081-.135
-.002-.036
.005-.060
-.085-.026
.011-.057
.081-.135
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P value
<.001
<.001
<.001
0.246
<.001
0.010
0.117
0.361
<.001
0.940
0.027
0.448
0.048
0.017
0.008
<.001
0.161
0.002
<.001
0.249
0.396
<.001
<.001
0.650
0.017
0.303
0.003
<.001

Table 10:
Gap Entry by Gap Group and Gender
Gender Label
Male=1
Female=2

Gap 1:
70.6%
66.1%

Gap 2
20.9%
24.7%

Gap 3
8.5%
9.2%

Table 11:
Adherence by Condition and Gap Entry Group 1

Condition Variable Name
hptnz_sc: Hypertension
diabz_sc: Diabetes
hlpz-sc: High Cholesterol
arthz_sc: Arthritis
deprz_sc: Depression
copdz_sc: Asthma

Mean
-0.072
-0.075
-0.104
-0.094
-0.144
-0.077

Gap Group 1
95% CI
95% CI
Number
(low)
(High)
of Obs
-0.083
-0.032
3299
-0.102
-0.049
852
-0.119
-0.088
2103
-0.164
-0.025
270
-0.196
-0.091
441
-0.132
-0.022
575

Table 12:
Adherence by Condition and Gap Entry Group 2

Condition Variable Name
hptnz_sc: Hypertension
diabz_sc: Diabetes
hlpz-sc: High Cholesterol
arthz_sc: Arthritis
deprz_sc: Depression
copdz_sc: Asthma

Mean
-0.002
0.012
-0.011
0.009
0.017
-0.005

Gap Group 2
95% CI
95% CI
(low)
(High)
-0.014
-0.007
-0.027
-0.041
-0.025
-0.043

53

0.009
0.032
0.006
0.059
0.059
0.034

Number
of Obs
1501
596
1183
115
262
368

Table 13:
Adherence by Condition and Gap Entry Group 3

Condition Variable Name
hptnz_sc: Hypertension
diabz_sc: Diabetes
hlpz-sc: High Cholesterol
arthz_sc: Arthritis
deprz_sc: Depression
copdz_sc: Asthma

Mean
0.042
0.019
0.026
-0.018
0.013
0.056

Gap Group 3
95% CI
95% CI
(low)
(High)
0.016
-0.001
-0.001
-0.092
-0.029
0.019

Table 14:
Analysis of Variance by Hypertension
Hypertension: Number of Obs: 4626
Variable Name:
P Value
<.001
Model
<.001
Gap
0.203
Sex
0.167
Age by Group
0.508
Education by year
0.028
Income Group
0.037
BMI
0.324
Reported Health
0.233
Region
0.651
Mental Health
0.915
Race
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0.068
0.039
0.052
0.057
0.056
0.092

Number
of Obs
588
332
491
62
133
217

Table 15:
Analysis of Variance by Diabetes
Diabetes Number of Obs: 1383
Variable Name:
P Value
<.001
Model
<.001
Gap
0.601
Sex
0.079
Age by Group
<.001
Education by year
0.035
Income Group
0.088
BMI
0.581
Reported Health
0.439
Region
0.609
Mental Health
0.460
Race

Table 16:
Analysis of Variance by High Cholesterol
High Cholesterol Number of Obs: 3181
Variable Name:
P Value
<.001
Model
<.001
Gap
0.213
Sex
0.622
Age by Group
0.069
Education by year
0.003
Income Group
0.001
BMI
0.078
Reported Health
0.507
Region
0.195
Mental Health
0.636
Race
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Table 17:
Analysis of Variance by Arthritis
Arthritis Number of Obs: 246
Variable Name:
P Value
0.201
Model
0.071
Gap
0.852
Sex
0.879
Age by Group
0.426
Education by year
0.533
Income Group
0.032
BMI
0.318
Reported Health
0.705
Region
0.025
Mental Health
0.217
Race
Table 18:
Analysis of Variance by Depression
Depression Number of Obs: 600
Variable Name:
P Value
0.001
Model
<.001
Gap
0.409
Sex
0.551
Age by Group
0.465
Education by year
0.249
Income Group
0.036
BMI
0.510
Reported Health
0.690
Region
0.153
Mental Health
0.587
Race
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Table 19:
Analysis of Variance by Asthma
Asthma Number of Obs: 884
Variable Name:
P Value
0.001
Model
0.001
Gap
0.563
Sex
0.019
Age by Group
0.797
Education by year
0.023
Income Group
0.355
BMI
0.154
Reported Health
0.058
Region
0.276
Mental Health
0.213
Race
Table 20:
Number of Prescriptions for Males by Gap Group

Gap By Group
Gap 1
Gap 2
Gap 3

Males
Mean 95% CI (low)
95% CI (High)
25.36
24.76
25.98
35.23
34.36
36.11
36.72
35.5
37.92

Number of
Obs
7836
5548
4654

Table 21:
Number of Prescriptions for Females by Gap Group

Gap By Group
Gap 1
Gap 2
Gap 3

Females
Mean 95% CI (low)
95% CI (High)
29.39
28.68
30.09
36.65
35.53
37.53
37.54
36.54
38.54
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Number of
Obs
8625
6613
6099
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